Related Experiment Video
Updated: Jun 16, 2026
10:31
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
Statin-associated weakness in myasthenia gravis: a case report
Michael J Keogh1, John M Findlay, Simon Leach
1Department of Stroke Medicine, United Lincolnshire Hospitals Trust, Lincoln County Hospital, Lincoln, LN2 5QY, UK. mikekeogh@doctors.org.uk.
Journal of Medical Case Reports
|February 23, 2010
Summary
Myasthenia gravis, an autoimmune condition, is often missed in older adults. Statin drug use may worsen or trigger symptoms, as seen in a case study of a patient with acute bulbar weakness.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Myasthenia gravis is frequently underdiagnosed in the elderly population.
- Statin medications are associated with muscle weakness and autoimmune conditions.
- Autoimmune conditions, including myasthenia gravis, can be exacerbated by statin use.
Purpose of the Study:
- To highlight the underappreciated role of myasthenia gravis in elderly patients presenting with acute bulbar weakness.
- To report a case where statin therapy potentially contributed to the onset and progression of myasthenia gravis.
Main Methods:
- Case report of a 60-year-old male with acute onset dysarthria and dysphagia.
- Initial misdiagnosis as a brain stem stroke.
- Diagnosis of myasthenia gravis after progression of oculobulbar and limb weakness, with subsequent statin withdrawal.
Main Results:
- The patient presented with symptoms mimicking a stroke, including difficulty speaking and swallowing.
- Progressive weakness in the eyes, face, and limbs indicated a neuromuscular disorder.
- Diagnosis of myasthenia gravis was confirmed, and symptoms improved after statin cessation.
Conclusions:
- Myasthenia gravis should be considered in the differential diagnosis of acute bulbar weakness in the elderly.
- Statin therapy may be a contributing factor to the development or worsening of myasthenia gravis.
- Prompt diagnosis and management, including medication review, are crucial for improving patient outcomes.
Related Concept Videos
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:28Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...